AMO Pharma reports Phase II data for myotonic dystrophy candidate

By Jennie Walters | Mar 30, 2018 | 5:46 PM GMT

AMO Pharma Ltd. (Surrey, U.K.) reported data from a Phase II trial in 16 patients ages 13-34

Read the full 176 word article

How to gain access

Continue reading with a
two-week free trial.